Medicinal Genomics, Inc. (OTCQB: MGEN) is a biotechnology company focused on the science, development and commercialization of cannabis-based therapeutics. The company’s core technology, Medicinal Genomics’ “Cannabis Genome ProjectTM,” leverages the power of genomics to bring the benefits of modern biotechnology to the cannabis plant.
Sherman Hom is a true believer in the value of the medical cannabis space and will be working to implement a policy agenda that will help us achieve our mission of improving the lives of patients around the globe.
According to a press release published last week, Medicinal Genomics has hired Sherman Hom, Ph.D. to be their first director of regulatory affairs. Dr. Hom is coming from a position at New Jersey’s Division of Public Health and Environmental Laboratories (PHEL) where he was the leading research scientist for the state’s cannabis testing lab as well as coordinating their pre-analytical activities for SARS-CoV-2 testing. Sherman Hom, Director of Regulatory Affairs at Medicinal Genomics As project manager for the state’s cannabis testing lab, he was responsible for validating microbial testing in cannabis. He has also been a professor of microbiology, a lab manager, a senior research scientist, a writer and an inventor, according to the press release. “My passion is regulatory affairs,” says Dr. Hom. “For the last 4 years, we’ve been building a facts and comparison database of required state medical cannabis testing. It’s formidable. Of course, the states will all have the same regulations eventually. In the meantime, it’s my job to help them craft the safest, most efficient and effective set of regulations possible. I’m here because I know Medicinal Genomics shares that passion.”